This phase I/II trial will investigate the use of the novel oral IRAK-4 inhibitor CA-4948 in combination with pembrolizumab therapy following stereotactic radiosurgery in patients with melanoma brain metastases (MBM). The investigators hypothesize鈥�
- Investigator
- Bently P Doonan
- Status
- Accepting Candidates
- Ages
- 18 Years - 99 Years
- Sexes
- All